Core Viewpoint - MoonLake Immunotherapeutics is facing a securities fraud class action lawsuit due to alleged misrepresentations regarding its clinical data and the efficacy of its investigational drug sonelokimab [1][3][4]. Group 1: Lawsuit Details - A lawsuit has been filed against MoonLake and certain senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][3]. - Investors have until December 15, 2025, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Southern District of New York [3]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its investigational drug sonelokimab [4]. - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated a higher clinical response for patients, suggesting a competitive advantage over traditional monoclonal antibody treatments [5]. Group 3: Allegations and Impact - The lawsuit alleges that the clinical data and Nanobody structure of sonelokimab did not provide a superior clinical benefit compared to competitors, raising doubts about the drug's regulatory approval and commercial viability [6]. - Following the announcement of disappointing results from the Phase 3 VELA trials, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share within a few days [7].

JEFFERIES NOTICE: Jefferies Financial Group Inc. (JEF) Investors are Notified of Securities Fraud Investigation and to Contact BFA Law if You Suffered LossesDecember 12, 2025 8:36 AM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 12, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Jefferies Financial Group Inc. (NYSE: JEF) and Point Bonita Capital for potential violations of the federal securities laws after SEC ...

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc for securities fraud, following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in James Hardie common stock [3]. - Investors have until December 23, 2025, to request to be appointed to lead the case [3]. Group 2: Company Background - James Hardie is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the U.S. and Canada [4]. Group 3: Allegations and Stock Performance - The complaint alleges that James Hardie misrepresented the strength and momentum of its North American fiber cement segment, claiming that sales were driven by sustainable customer demand rather than inventory loading by channel partners [5]. - On August 19, 2025, James Hardie reported a 12% decline in North American fiber cement sales, leading to a stock price drop of over 34%, from $28.43 to $18.64 per share [6]. Group 4: Management Changes - On November 17, 2025, it was announced that Rachel Wilson would step down from her role as CFO [7].

LOS ANGELES, Dec. 11, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors of the upcoming January 30, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired DeFi Technologies Inc. ("DeFi" or the “Company") (NASDAQ: DEFT) securities between May 12, 2025 and November 14, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON DEFI (DEFT), CLICK HERE TO PARTICIPATE IN THE SECURITIES F ...

Core Viewpoint - A class action lawsuit has been filed against Bitdeer Technologies Group for allegedly misleading investors regarding its financial performance and the development of its next-generation ASIC chip [1][5]. Financial Performance - On November 10, 2025, Bitdeer reported a per-share loss of $1.28 for Q3 2025, significantly worse than the expected loss of $0.22 [3]. - Following the announcement, Bitdeer's stock price dropped by $2.63, or 14.90%, closing at $15.02 per share on November 11, 2025 [4]. Lawsuit Details - The lawsuit claims that Bitdeer made materially false and misleading statements throughout the class period, failing to disclose significant adverse facts about its business and operations [5]. - Specifically, the complaint highlights that the development of the SEAL04 chip, which was expected to have a chip-level energy efficiency of 5 J/TH, faced substantial delays, contradicting earlier positive statements made by the company [5].

Core Viewpoint - Blue Owl Capital Inc. is facing a class action lawsuit due to allegations of misleading statements and undisclosed liquidity issues that have negatively impacted investors during the Class Period from February 6, 2025, to November 16, 2025 [1][4]. Group 1: Company Actions and Events - On November 16, 2025, it was reported that Blue Owl has blocked redemptions in one of its private credit funds as it merges with a larger vehicle, potentially leading to significant losses for investors [2]. - Following the announcement of the merger, investors in Blue Owl Capital Corporation II will lose the ability to redeem cash at the fund's Net Asset Value (NAV) and will instead exchange their shares for publicly traded Blue Owl shares, which are currently trading approximately 20% below the fund's NAV [3]. - The stock price of Blue Owl fell by as much as 6% during intraday trading on November 17, 2025, indicating a negative market reaction to the news [3]. Group 2: Legal Proceedings - The class action lawsuit alleges that Blue Owl's management made materially false and misleading statements and failed to disclose critical information regarding the company's asset base and liquidity issues [4]. - The lawsuit claims that the company was under pressure from Business Development Company (BDC) redemptions, which led to undisclosed liquidity problems and the likelihood of limiting or halting redemptions [4]. - Investors who purchased Blue Owl securities during the Class Period have until February 2, 2026, to file a lead plaintiff motion in the class action lawsuit [5].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Bitdeer Technologies Group securities between June 6, 2024, and November 10, 2025, due to alleged misleading statements regarding the company's SEALMINER Bitcoin mining machine [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Bitdeer provided investors with positive information about its SEALMINER A4 rigs and their expected energy efficiency of 5 J/TH while failing to disclose critical facts about the project's true state [5][6]. - Defendants allegedly made false statements that led to investors purchasing Bitdeer securities at artificially inflated prices, resulting in damages when the true information became public [6]. Group 2: Participation Information - Investors who purchased Bitdeer securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][7].

Core Viewpoint - The lawsuit against Perrigo Company plc alleges that the company made materially false statements and failed to disclose significant issues regarding its infant formula business, leading to overstated financial results [3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Perrigo securities from February 27, 2023, to November 4, 2025, alleging misleading statements about the infant formula business [3]. - Specific allegations include underinvestment in maintenance and operational improvements, the need for substantial capital expenditures beyond stated estimates, and significant manufacturing deficiencies [3]. Group 2: Financial Impact - On November 5, 2025, Perrigo reported its third-quarter financial results and lowered its full-year guidance due to poor OTC consumption and issues with the infant formula business [4]. - Following this announcement, Perrigo's share price dropped by $5.09, approximately 25.2%, from $20.19 to $15.10 [4].

The lawsuit has been filed on behalf of investors who purchased securities pursuant to the registration statement and prospectus (collectively "offering documents†) issued in connection with the Company's September 2025 initial public offering ("IPO†). The lawsuit alleges that, in connection with its IPO, StubHub failed to disclose to investors that: (1) the Company was experiencing changes in the timing of payments to vendors; (2) those changes had a significant adverse impact on free cash flow, includ ...

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Perrigo Company plc (NYSE: PRGO). Shareholders who purchased shares of PRGO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/perrigo-company-plc-loss-submission-form/?id=180006&from=3  CLASS PERIOD: Februa ...